Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial
Open Access
- 31 March 2004
- journal article
- abstracts
- Published by Elsevier in European Journal of Cancer Supplements
- Vol. 2 (3) , 125-126
- https://doi.org/10.1016/s1359-6349(04)90842-7
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: